The characterization of a local reninangiotensin system in the pancreas has attracted much attention because of its potential clinical applications. A pancreatic renin-angiotensin system may be present in humans and may interact with islet cells.
Nevertheless, our knowledge of the reninangiotensin system in the human pancreas is still in its infancy, especially in the field of endocrine oncology. Much of our knowledge stems from the study of the pancreas and pancreatic endocrine tumors of rodents. Thus, the direction of future research should be based on in-depth and collaborative efforts between researchers in the various disciplines in order to apply the newly acquired scientific knowledge to the patient.
Pancreatic endocrine tumors are endocrine tumors arising from the cells in the pancreatic islet. They account for approximately 10% to 15% of primary pancreatic tumors. The tumors are divided into two groups, functional and non-functional tumors. Functional tumors are those with clinical or biochemical evidence of hormonal production. These tumors are typed according to the hormonal syndromes they produce and are called by names such as insulinoma, glucagnonoma, gastrinoma, etc. Pancreatic endocrine tumors present an important challenge to the clinical management team because of their proteic manifestations, potential lethality and difficulty in predicting the clinical behavior.
The Pancreatic Renin-Angiotensin System: Does It Play a Role in Endocrine Oncology?: King-Yin Lam
Last date updated on September, 2020